Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Feng

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 9, 2024
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After InjectionSurekha Yadav, Fei Jiang, Sara Kurkowska, et al.
Practical Radiation Oncology|December 12, 2022
Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiation TherapyThomas J Quinn, Daniel Chapman, Jacob Parzen, et al.
Seminars in Radiation Oncology|June 18, 2023
Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation OncologyPhilip Sutera, Heath Skinner, Matthew Witek, et al.
Prostate Cancer and Prostatic Diseases|August 11, 2024
Delayed definitive management of localized prostate cancer: what do we know?Osama Mohamad, Yun Rose Li, Felix Feng, et al.
European Urology|May 18, 2024
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate CancerSabine D Brookman-May, Marc Buyse, Stephen J Freedland, et al.
European Urology Oncology|April 19, 2020
Intermediate-risk Prostate Cancer: Stratification and ManagementFelix Preisser, Matthew R Cooperberg, Juanita Crook, et al.
Clinical Epigenetics|May 5, 2022
Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancerTesa Severson, Xintao Qiu, Mohammed Alshalalfa, et al.
European Urology Focus|January 16, 2019
What Is Oligometastatic Prostate Cancer?Michael Fraser, Bridget Koontz, Urban Emmenegger, et al.
Molecular Oncology|February 19, 2019
The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional programAbhijit Parolia, Erik Venalainen, Hui Xue, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 15, 2024
Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP databasePascal Pommier, Wanling Xie, Praful Ravi, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 9, 2024
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After InjectionSurekha Yadav, Fei Jiang, Sara Kurkowska, et al.
Practical Radiation Oncology|December 12, 2022
Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiation TherapyThomas J Quinn, Daniel Chapman, Jacob Parzen, et al.
Seminars in Radiation Oncology|June 18, 2023
Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation OncologyPhilip Sutera, Heath Skinner, Matthew Witek, et al.
Prostate Cancer and Prostatic Diseases|August 11, 2024
Delayed definitive management of localized prostate cancer: what do we know?Osama Mohamad, Yun Rose Li, Felix Feng, et al.
European Urology|May 18, 2024
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate CancerSabine D Brookman-May, Marc Buyse, Stephen J Freedland, et al.
European Urology Oncology|April 19, 2020
Intermediate-risk Prostate Cancer: Stratification and ManagementFelix Preisser, Matthew R Cooperberg, Juanita Crook, et al.
Clinical Epigenetics|May 5, 2022
Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancerTesa Severson, Xintao Qiu, Mohammed Alshalalfa, et al.
European Urology Focus|January 16, 2019
What Is Oligometastatic Prostate Cancer?Michael Fraser, Bridget Koontz, Urban Emmenegger, et al.
Molecular Oncology|February 19, 2019
The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional programAbhijit Parolia, Erik Venalainen, Hui Xue, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 15, 2024
Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP databasePascal Pommier, Wanling Xie, Praful Ravi, et al.
Pageof 8